Beigene LTD. – American Depositary Shares (NASDAQ:BGNE) had a decrease of 2.83% in short interest. BGNE’s SI was 1.94M shares in April as released by FINRA. Its down 2.83% from 2.00M shares previously. With 615,600 avg volume, 3 days are for Beigene LTD. – American Depositary Shares (NASDAQ:BGNE)’s short sellers to cover BGNE’s short positions. The SI to Beigene LTD. – American Depositary Shares’s float is 11.48%. The stock decreased 0.95% or $1.6 during the last trading session, reaching $166.62. About 179,924 shares traded. BeiGene, Ltd. (NASDAQ:BGNE) has risen 354.57% since April 17, 2017 and is uptrending. It has outperformed by 343.02% the S&P500.
Analysts expect Altimmune, Inc. (NASDAQ:ALT) to report $-0.50 EPS on May, 2.They anticipate $0.20 EPS change or 66.67% from last quarter’s $-0.3 EPS. After having $-0.12 EPS previously, Altimmune, Inc.’s analysts see 316.67% EPS growth. The stock decreased 2.79% or $0.024 during the last trading session, reaching $0.836. About 363,614 shares traded or 32.38% up from the average. Altimmune, Inc. (NASDAQ:ALT) has declined 84.57% since April 17, 2017 and is downtrending. It has underperformed by 96.12% the S&P500.
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $15.14 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $8.87 billion. The companyÂ’s clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.